Clinical Trial Update: Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cabazitaxel plus prednisone in metastatic hormone-resistant prostate cancer was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Cabazitaxel (cabazitaxel)
• PREDNISONE (Prednisone)

Snippet

Sponsor: University of California, Davis | Conditions: Hormone-Resistant Prostate Cancer, Stage IV Prostate Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2021-01-25